OpenEvidence Moves Inside NYU Langone's Epic Chart

Good morning, HealthTech insiders. A chatbot that now lives inside the chart, a wristband that keeps working after the ablation catheter comes out, and an AI agent that reads rebate contracts nobody had time to check. On the surface, yesterday's three biggest moves share nothing. Look closer and they share a destination: the place where the work already happens.

OpenEvidence is now embedded in NYU Langone's Epic workflow, inside a system that logs 12.4 million outpatient visits a year. StimCardio closed a $30M Series A to take Rhyvive, its investigational wrist-worn neuromodulation therapy for atrial fibrillation, into a pivotal trial. Midstream Health raised $20M to find missed revenue across more than 250 hospitals. Today's Signal is about distribution: who gets to sit inside the workflow, the home and the general ledger, and what they have to prove once they get there.

In today's Signal:

• OpenEvidence and NYU Langone Health embed patient-aware clinical AI inside Epic across hospitals, 400+ outpatient locations and the Family Health Centers.

• StimCardio closes an oversubscribed $30M Series A led by Metis Medtech to fund the NeuroPulse 2 pivotal study of Rhyvive and De Novo preparation.

• Midstream Health raises a $20M Series A led by Valtruis, taking total funding to $29.2M for its AI financial operations platform for health systems.

In partnership with

7 Stocks Built to Hold Forever. See the Full List.

Chasing the next hot stock can be exhausting, and it rarely builds wealth the way investors expect. The strongest long-term portfolios are often anchored by durable, blue-chip businesses designed to withstand recessions, inflation and shifting market leadership.

MarketBeat’s free 7 Stocks to Buy and Hold Forever report identifies companies across technology, retail, consumer staples, healthcare, networking, sporting goods and utilities. Each offers its own mix of stability, income, growth and staying power.

These are not speculative names built around the latest headline. They are established businesses selected for investors who would rather own quality companies for years than constantly chase the market.

Get your complimentary copy and see all seven names today.

Get the Free Report

CLINICAL AI
1. OpenEvidence Moves Inside NYU Langone's Epic Chart, Covering 12.4 Million Outpatient Visits a Year

OpenEvidence and NYU Langone Health announced a collaboration that embeds OpenEvidence directly in NYU Langone's Epic EHR with what the partners call Patient Aware Clinical Intelligence, so clinicians can ask natural-language clinical questions and get literature-grounded answers with patient context without leaving the chart.

The details:

• Scale: 12.4 million outpatient visits and more than 421,000 ED visits a year across seven inpatient locations and more than 400 outpatient locations, plus the Family Health Centers (about 600,000 visits a year) and trainees at NYU Grossman and NYU Grossman Long Island schools of medicine.

• Fierce Healthcare frames the deal as an expansion of OpenEvidence's New York footprint, which already includes NewYork-Presbyterian and Mount Sinai. Named leaders: Nader Mherabi, EVP, vice dean and chief digital and information officer at NYU Langone, and Daniel Nadler, founder and CEO of OpenEvidence.

• Context: a JAMA study published Oct 15 logged 271 million queries from 952,008 US clinicians between January 2024 and June 2026. It measured usage, not answer accuracy or patient outcomes.

The Signal: Clinical AI search is turning from a free app clinicians open on their phones into an enterprise-sanctioned layer inside the EHR. That moves the buyer from the individual physician to the CIO, and it moves the question from whether clinicians like it to who audits patient-context answers at system scale. Expect logging, governance and outcome measurement to become the next procurement asks, not usage counts.

MEDTECH
2. StimCardio Closes $30M Series A to Take a Wrist-Worn AF Neuromodulation Therapy Into a Pivotal Trial

Los Angeles-based StimCardio closed an oversubscribed $30M Series A led by John Slump's family office, Metis Medtech, with Catalyst Health Ventures and multiple corporate strategic investors, to fund the NeuroPulse 2 pivotal study of Rhyvive and preparation of a De Novo submission to the FDA.

The details:

• Rhyvive is an investigational, wrist-worn, closed-loop device that delivers median nerve stimulation as an adjunct to catheter ablation, aiming to reduce AF recurrence at home. It is limited by US law to investigational use.

• The randomized, double-blind, sham-controlled NeuroPulse pilot (77 patients randomized, 59 in the modified intention-to-treat analysis) reported 12 recurrent atrial arrhythmia events with stimulation versus 28 with sham (p = 0.025). Six-month freedom from atrial arrhythmia was 90.0% versus 80.8%, a difference that was not statistically significant. Results were presented at HRX Live 2026 and published in Heart Rhythm.

• CEO is Amir Soltanianzadeh. Slump, now a StimCardio board member, cites prior exits including Farapulse and Atraverse Medical.

The Signal: The bet is not really the wristband. It is that the next gain in AF outcomes may come after the procedure rather than from a better catheter. The company cites 30% to 40% recurrence after a first ablation, even as pulsed field ablation spreads. If NeuroPulse 2 replicates the event reduction on a hard endpoint, electrophysiologists get a prescribable home therapy and strategics get a post-ablation revenue line. If it does not, the pilot's non-significant freedom figure becomes the headline.

HOSPITAL OPS
3. Midstream Health Raises $20M Series A to Hunt Missed Revenue and Rebates Across 250+ Hospitals

Midstream Health, which sells an autonomous AI financial operations platform to health systems, raised a $20M Series A led by Valtruis, with Andreessen Horowitz, Foundry and CommonSpirit Ventures participating, bringing total funding to $29.2M.

The details:

• The platform reads contracts, invoices, claims and payments to flag pricing errors, insurer underpayments and missed rebates, then helps prepare and submit recovery claims, according to MobiHealthNews.

• The company says its footprint spans 250+ hospitals and more than $100B in annual operating expenses. Fairview and Keck Medicine of USC are the newest systems, alongside CommonSpirit, Mount Sinai and Houston Methodist.

• Company-reported: more than 1,500 recovery opportunities identified this year and on pace for $100M in client savings by the end of 2026. Co-founder and CEO is Sumit Kadakia.

The Signal: Revenue cycle AI has mostly fought over denials and coding. Midstream is going after a quieter leak: the gap between what a hospital negotiated and what it actually got paid or charged. That is a finance-office product with a CFO buyer and a dollar figure attached, which is why health-system venture arms keep turning up on these cap tables. The test is whether the savings are audited cash recoveries or identified opportunities.

👀 WHAT WE'RE WATCHING NEXT

• OpenEvidence at NYU Langone: Whether NYU Langone publishes usage, answer-audit or outcome data from inside Epic, and whether another top academic system announces a chart-embedded deployment this quarter.

• StimCardio NeuroPulse 2: A ClinicalTrials.gov registration with the primary endpoint, enrollment target and sites, plus any FDA Breakthrough Device designation or De Novo pre-submission language.

• Midstream Health: Whether the $100M 2026 savings figure is reported as cash recovered or opportunities identified, and new health-system logos beyond the five named this week.

💰 FOLLOW THE MONEY

The deals:

• Midstream: $20M Series A with Valtruis, a16z, Foundry and CommonSpirit Ventures to help hospitals ensure payments match agreed contract terms.

• SpendRule: $4M seed led by Mark Cuban’s Radical Investments. The company reports covering $2.91B in contracted purchased-services spend across customers including OSF HealthCare, Kettering Health, MemorialCare and MUSC Health, not money recovered.

• StimCardio: $30M round led by an operator-investor whose track record includes Farapulse, highlighting the role of experienced backers in cardiac electrophysiology.

• OpenEvidence: NYU Langone deal expands enterprise distribution, adding a major institutional customer rather than new financing.

The pattern: Capital is backing infrastructure that helps hospitals control spending and enforce contract terms. In cardiac electrophysiology, experienced operators remain a draw for investors, while clinical AI companies are building their commercial case through major enterprise customers. The common thread is a clearer route into hospital budgets through measurable savings, established relationships or institutional adoption.

📆 UPCOMING HEALTHTECH EVENTS

• MEDICA 2026: November 16-19, 2026 · Messe Düsseldorf, Germany

  Europe's largest MedTech trade fair, where wearable therapeutics and EU MDR pathways meet buyers.

• RSNA 2026: November 29 - December 3, 2026 · McCormick Place, Chicago, IL

  Radiology's annual meeting and the busiest stage for imaging AI clearances and enterprise deals.

• 45th Annual J.P. Morgan Healthcare Conference: January 11-14, 2027 · San Francisco, CA

  Where 2027 guidance, M&A and HealthTech financing narratives get set for the year.

🛠️ Trending HealthTech AI Tools

• Cardiolyse ECG Workspace. Launched Oct 29: a browser-based 12-lead resting ECG review space where AI proposes measurements and findings, and clinicians inspect every lead, edit and sign the final report. A central worklist tracks studies across sites and devices.

• Deep Breathe BlineSlide. FDA 510(k) K261679, cleared Oct 23, 2026, for AI detection of absent lung sliding in lung ultrasound video. Useful for point-of-care pneumothorax assessment; absent sliding is suggestive, not diagnostic.

• Notable Flow Compass. Launched Oct 19: a conversational layer inside Notable's Flow Studio for testing, monitoring and governing AI agent workflows, with audit trails for governance.

🛠️ Trending HealthTech AI Startups

• SpendRule: Dallas-based contract verification AI raised a $4M seed (Oct 29) led by Radical Investments, Mark Cuban's firm, with Zeal Capital Partners; total funding $6M. Co-CEOs Chris Heckler and Joseph Akintolayo. Strategic interest: purchased-services leakage as a new hospital margin line.

• Ozlo: Sleep technology company raised a $22M Series B (Oct 29) led by Modi Ventures to expand beyond Sleepbuds into biosensing and sleep health, including regulatory preparation for a tinnitus product intended for FDA review. Strategic interest: consumer sleep hardware moving toward regulated claims.

• Wrapped Health: Raised a $2.1M pre-seed (Oct 29) co-led by Lightbank and Arteria Capital for provider-reviewed over-the-counter recommendations sent from the EHR, live on the athenahealth Marketplace for more than 180,000 athenaOne clinicians. Strategic interest: EHR marketplaces as a distribution channel for consumer health.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

1. The Chart Is the Channel: What OpenEvidence Inside NYU Langone's Epic Means for Clinical AI. A free clinician app becomes enterprise infrastructure across 12.4 million visits, and the proof bar shifts from usage to audited answers.

2. After the Ablation: StimCardio, Wearable Neuromodulation and the Next AF Outcome Gap. A $30M Series A funds a pivotal trial for a home therapy that targets recurrence rather than the catheter.

3. The Leakage Economy: Why Hospital Finance AI Is Moving From Denials to Contracts. Midstream's $20M and SpendRule's $4M point to a CFO-owned category built on recoverable dollars.

That's it for today!

A chatbot in the chart, a wristband after the catheter and an agent in the accounts payable queue. Each is trying to earn a permanent seat somewhere the old tools never reached. The ones that keep the seat will be the ones that publish what happened next: answers audited, arrhythmias avoided, dollars actually returned to the hospital.

So when your next committee meets, which number will you ask for first: the usage figure everyone already has, or the outcome figure nobody has published yet?

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.